The effect of ipraglifozin on circadian rhythm in blood glucose using CGM in type 2 diabetes

The effect of ipraglifozin on circadian rhythm in blood glucose using CGM in type 2 diabetes - The effect of ipraglifozin on circadian rhythm in blood glucose using CGM in type 2 diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014190

Enrollment

Registered

2014-06-09

Start date

2014-06-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

ipragliflozin 50mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)before test registration - the meal and exercise cure for one month or more or a meal and an exercise cure, and diabetic medicine and inpatient 2)HbA1c (JDS):more than 7.0%, less than 9.0% 3)eGFR more than 45ml/min/1.73m 2 4)Type diabetes 5)Pts with written IC 6)Age more than 20, less than 85

Exclusion criteria

Exclusion criteria: 1)severe ketosis, diabetic coma within 6 months 2)severe infection, before operation, severe trauma 3)severe hepatic dysfunction 4)or severe renal dysfunction (Cr: more than 1.5mg/dl) 5)Patients who use of insulin 6)pregnacy 7)Allergy for sitagliptin, nateglinide,liraglutide and exenatide 8)Patients judged by the investigator to be ineligible for some other reason

Design outcomes

Primary

Measure	Time frame
Standard deviation of blood glucose by CGM	—

Secondary

Measure	Time frame
1)averate blood glucose, MAGE by CGM 2)FPG and PPG at 1, 2, 3, 4, 5, 6, 7 days of treatment 3)%chagne of FPG, HbA1c,IRI,CPR, a from baseline	—

Countries

Japan

Contacts

Public ContactJoe Nagakura

Yokohama City University Medical Center Department of Endocrinology and Diabetes

jo0806nagakura@hotmail.com045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026